GlassScriptPhysician profile
Scott A Bralow
NPI 1174586358
$6,605.22
in general payments reported to CMS, 2019-2025
34 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $270 · 2021: $664 · 2022: $863 · 2023: $1,225 · 2024: $1,385 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051 · Education: $44.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.70 |
| Education | $44.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,228.80 | 2021-2025 | |
| Lilly USA, LLC | $844.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $804.36 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $641.69 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $515.90 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $373.76 | 2019-2025 | Jynarque, Voyxact |
| Pfizer INC. | $235.05 | 2023-2025 | |
| Amgen INC. | $228.42 | 2019-2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.08 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $174.97 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $164.74 | 2019 | |
| Eisai INC. | $115.98 | 2021-2024 | |
| Ardelyx, INC. | $115.54 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $113.04 | 2019-2025 | Vafseo, Auryxia |
| Exact Sciences Corporation | $103.77 | 2024-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $101.57 | 2020-2025 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.87 | 2019-2025 | Jardiance, Synjardy |
| Vifor Pharma, INC. | $80.70 | 2019-2023 | Veltassa |
| Idorsia Pharmaceuticals US INC | $59.00 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $58.58 | 2023-2024 | |
| Gilead Sciences, INC. | $48.22 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.54 | 2022 | |
| Abbott Laboratories | $43.56 | 2024-2025 | Freestyle Libre 3 |
| Fresenius USA Marketing, INC. | $37.53 | 2020-2022 | |
| Optos, INC. | $22.45 | 2020 | |
| Hologic Sales and Service, LLC | $21.88 | 2024 | Aptima |
| Concordia Pharmaceuticals INC. | $19.30 | 2019 | |
| Glaxosmithkline, LLC. | $19.03 | 2022 | |
| Allergan, INC. | $18.46 | 2020 | |
| Merck Sharp & Dohme LLC | $16.20 | 2020 | |
| Linus Health, INC. | $15.25 | 2023 | |
| Seqirus USA INC | $15.00 | 2020 | |
| Esperion Therapeutics, INC. | $14.57 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.14 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bralow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.